TELA Bio (NASDAQ:TELA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials […]
TELA Bio, Inc. (NASDAQ:TELA – Get Rating) insider Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock in a transaction that occurred on Thursday, March 31st. The shares were purchased at an average cost of $11.54 per share, for a total transaction of $57,700.00. The transaction was disclosed in a legal filing […]
TELA Bio, Inc. (NASDAQ:TELA – Get Rating) insider Ew Healthcare Partners Fund 2, acquired 3,052 shares of TELA Bio stock in a transaction on Tuesday, March 29th. The stock was acquired at an average cost of $11.65 per share, for a total transaction of $35,555.80. The transaction was disclosed in a legal filing with the […]
TELA Bio, Inc. (NASDAQ:TELA – Get Rating) – Equities researchers at Jefferies Financial Group cut their Q1 2022 EPS estimates for TELA Bio in a report released on Monday, March 21st. Jefferies Financial Group analyst Z. Weiner now anticipates that the company will post earnings of ($0.44) per share for the quarter, down from their […]
TELA Bio (NASDAQ:TELA – Get Rating) posted its quarterly earnings data on Monday. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.01), MarketWatch Earnings reports. TELA Bio had a negative return on equity of 84.60% and a negative net margin of 121.27%. During the same period in the […]